A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Latest Information Update: 21 Nov 2025
At a glance
- Drugs SBT-77-7101 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Acronyms Regulate-RA
- Sponsors Sonoma Biotherapeutics
Most Recent Events
- 29 Oct 2025 Interim results presented in the Sonoma Biotherapeutics Media Release
- 29 Oct 2025 According to Sonoma Biotherapeutics media release, company is looking forward for completion of the ongoing dose escalation of SBT-77-7101 and its advancement into the dose expansion phase
- 14 Oct 2025 According to Sonoma Biotherapeutics media release, data from this trial will be presented at the 2025 American College of Rheumatology (ACR) Convergence